Why an Obscure Washington Firm Could Threaten Big Pharma?

Dec 12, 2018 | Drug Pricing, ICER, Price Watch, Pricing

Drug Pricing

The Washington Examiner introduces readers to The Institute for Clinical Research and Economic Review (ICER), an obscure Washington DC firm that may worry some of the world’s biggest pharmaceutical companies. ICER evaluates prescription drugs to determine whether the list prices align with the clinical and economic value for patients. Follow the link below to read this interesting interview to learn more about this influential firm few have heard of.

0 Comments

Pin It on Pinterest